AT

Aera Therapeutics

www.aeratx.com link_icon

Company Research Report: Aera Therapeutics



Company Overview



  • Name: Aera Therapeutics

  • Mission: To harness enabling delivery technologies and precision payloads to develop transformative genetic medicines.

  • Founded: The exact founding date is not specified, but foundational technology was developed from research in the labs of Feng Zhang, Ph.D., at MIT and Harvard, and Jason Shepherd, Ph.D., at the University of Utah.

  • Founders: A distinguished set of industry leaders and company builders.

  • Key People:

  • Akin Akinc, Ph.D. - Chief Executive Officer

  • Feng Zhang, Ph.D. - Scientific Founder, Core Institute Member, Broad Institute of MIT and Harvard

  • John Maraganore, Ph.D. - Board Chair, Former and Founding CEO, Alnylam Pharmaceuticals

  • Robert Nelsen - Board Director, Co-founder and Managing Director, ARCH Venture Partners

  • Issi Rozen - Board Observer, General Partner, GV

  • Vicki Sato, Ph.D. - Board Director, Board Chair, Vir Biotechnology and Denali Therapeutics

  • David Schenkein, M.D. - Board Director, General Partner, GV

  • Josh Wolfe - Board Director, Co-founder and Managing Partner, Lux Capital

  • Headquarters: 300 Technology Square, Cambridge, MA 02139

  • Number of Employees: No information is available

  • Revenue: No information is available

  • Known For: Aera Therapeutics is known for its innovative approaches in genetic medicine, particularly its protein nanoparticle (PNP) delivery platform.


Products



  • Protein Nanoparticle (PNP) Delivery Platform

  • High-Level Description: Aera’s PNP delivery platform is based on the discovery of endogenous human proteins that self-assemble to form capsid-like structures, allowing them to package and transfer nucleic acid cargo.

  • Key Features:

  • Based on endogenous human proteins.

  • Provides a fully synthetic self-assembling system.

  • Combines the engineerability of a protein-based system.

  • Potential to enable various genetic medicine modalities.


  • Proprietary Therapeutic Enzyme Platform

  • High-Level Description: This platform includes novel, compact, and programmable gene editing enzymes, designed to overcome the packaging and delivery challenges associated with current gene editor systems.

  • Key Features:

  • Compact size of enzymes.

  • Programmability.

  • Overcomes challenges of current gene editing systems.


Recent Developments



  • Recent Financing: On February 16, 2023, Aera Therapeutics announced the launch with $193 million in financing aimed at enabling and advancing the next generation of transformative genetic medicines.

  • New Products Launched: No information is available

  • New Features Added to Existing Products: No information is available

  • New Partnerships: No information is available


This report is intended to provide a comprehensive overview of Aera Therapeutics based on the available data, focused on their efforts in the field of genetic medicines.